Open investigations
Tirzepatide
Investigation
Can medication change appetite
without replacing nutrition?
Approved
Last reviewed July 2026 · v1.1 frozen
Conversations
- Obesity
- Diabetes
- OSA
- HFpEF
- Maintenance
- Lean mass
Open folio →
Retatrutide
Investigation
What do you do with a therapy
that already dominates conversation
before it has a label?
Pipeline · Phase 3
Last reviewed July 2026 · v0.1 frozen
Conversations
- Obesity
- Triple agonist
- vs tirzepatide
- Access
- Heart rate
- Compounding
Open folio →
CagriSema
Investigation
What changes when a familiar GLP-1
is paired with amylin?
NDA filed · Phase 3 published
Last reviewed July 2026 · v0.1 frozen
Conversations
- Amylin
- Obesity
- Diabetes
- vs semaglutide
- Combination therapy
- GI burden
Open folio →
Orforglipron
Investigation
What is actually new when a GLP-1
arrives as a daily tablet
that isn’t a peptide?
Approved (weight)
Last reviewed July 2026 · v0.1 frozen
Conversations
- Oral GLP-1
- Non-peptide
- Foundayo
- vs injectables
- vs oral semaglutide
- Adherence
Open folio →
Survodutide
Investigation
When the dual is glucagon (not GIP),
and obesity and MASH develop
on different clocks,
what is the counseling object?
Pipeline · Phase 3
Last reviewed July 2026 · v0.1 frozen
Conversations
- Obesity
- MASH / MASLD
- Glucagon dual
- Two clocks
- Liver fat
- Breakthrough Therapy
Open folio →
GH
Secretagogues
Investigation · Class
How do you think clearly when patients
bring one name for several
different therapies?
Class review · evidence evolving
Last reviewed July 2026 · v0.1 frozen
Conversations
- Ipamorelin
- CJC-1295
- Sermorelin
- MK-677
- Stacks
- vs tesamorelin
Open folio →
BPC-157
Investigation
How do we evaluate a therapy
when enthusiasm outpaces
human evidence?
Evidence evolving
Last reviewed July 2026 · v0.1 frozen
Conversations
- Recovery
- Sports medicine
- Regulation
- Human evidence
- Product quality
Open folio →
TB-500
Investigation
Is the peptide in the vial
the same one the human trials studied?
Evidence evolving
Last reviewed July 2026 · v0.1 frozen
Conversations
- Thymosin β4 fragment
- vs BPC-157
- Recovery stacks
- Identity gap
- Compounding
- Sport ban
Open folio →
MOTS-c
Investigation · Thin
When does a strong mitochondrial story
become a therapy you can counsel?
Thin · evidence evolving
Last reviewed July 2026 · v0.1 frozen
Conversations
- Mitochondrial peptide
- AMPK
- Endogenous vs exogenous
- CB4211 analogue
- Insulin sensitivity
- Exercise mimetic
Open folio →
Tesamorelin
Investigation
When does one therapy legitimately
belong in several conversations?
Approved (HIV)
Last reviewed July 2026 · v0.1 frozen
Conversations
- VAT
- Liver fat
- GH axis
- Body composition
- Indication boundaries
Open folio →